GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Completed
GlaxoSmithKline
Phase 1
2004-03-01
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Giving
GW572016 with trastuzumab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given
together with trastuzumab in treating patients with metastatic breast cancer that
overexpresses HER2/neu.
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Completed
National Cancer Institute (NCI)
Phase 1
2004-03-01
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Giving
GW572016 with trastuzumab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given
together with trastuzumab in treating patients with metastatic breast cancer that
overexpresses HER2/neu.
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Completed
Jonsson Comprehensive Cancer Center
Phase 1
2004-03-01
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Giving
GW572016 with trastuzumab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given
together with trastuzumab in treating patients with metastatic breast cancer that
overexpresses HER2/neu.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.